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Summary
Background Current guidelines recommend potent platelet inhibition with prasugrel or ticagrelor for 12 months after 
an acute coronary syndrome managed with percutaneous coronary intervention (PCI). However, the greatest anti-
ischaemic benefit of potent antiplatelet drugs over the less potent clopidogrel occurs early, while most excess bleeding 
events arise during chronic treatment. Hence, a stage-adapted treatment with potent platelet inhibition in the acute 
phase and de-escalation to clopidogrel in the maintenance phase could be an alternative approach. We aimed to 
investigate the safety and efficacy of early de-escalation of antiplatelet treatment from prasugrel to clopidogrel guided 
by platelet function testing (PFT).
Methods In this investigator-initiated, randomised, open-label, assessor-blinded, multicentre trial (TROPICAL-ACS) 
done at 33 sites in Europe, patients were enrolled if they had biomarker-positive acute coronary syndrome with 
successful PCI and a planned duration of dual antiplatelet treatment of 12 months. Enrolled patients were randomly 
assigned (1:1) using an internet-based randomisation procedure with a computer-generated block randomisation with 
stratification across study sites to either standard treatment with prasugrel for 12 months (control group) or a step-
down regimen (1 week prasugrel followed by 1 week clopidogrel and PFT-guided maintenance therapy with clopidogrel 
or prasugrel from day 14 after hospital discharge; guided de-escalation group). The assessors were masked to the 
treatment allocation. The primary endpoint was net clinical benefit (cardiovascular death, myocardial infarction, 
stroke or bleeding grade 2 or higher according to Bleeding Academic Research Consortium [BARC]) criteria) 1 year 
after randomisation (non-inferiority hypothesis; margin of 30%). Analysis was intention to treat. This study is 
registered with ClinicalTrials.gov, number NCT01959451, and EudraCT, 2013-001636-22.
Findings Between Dec 2, 2013, and May 20, 2016, 2610 patients were assigned to study groups; 1304 to the guided de-
escalation group and 1306 to the control group. The primary endpoint occurred in 95 patients (7%) in the guided de-
escalation group and in 118 patients (9%) in the control group (pnon-inferiority=0·0004; hazard ratio [HR] 0·81 [95% CI 
0·62–1·06], psuperiority=0·12). Despite early de-escalation, there was no increase in the combined risk of cardiovascular 
death, myocardial infarction, or stroke in the de-escalation group (32 patients [3%]) versus in the control group 
(42 patients [3%]; pnon-inferiority=0·0115). There were 64 BARC 2 or higher bleeding events (5%) in the de-escalation group 
versus 79 events (6%) in the control group (HR 0·82 [95% CI 0·59–1·13]; p=0·23).
Interpretation Guided de-escalation of antiplatelet treatment was non-inferior to standard treatment with prasugrel at 
1 year after PCI in terms of net clinical benefit. Our trial shows that early de-escalation of antiplatelet treatment can 
be considered as an alternative approach in patients with acute coronary syndrome managed with PCI.
Funding Klinikum der Universität München, Roche Diagnostics, Eli Lilly, and Daiichi Sankyo.
Introduction
Activation of blood platelets plays a key part both in the 
initiation and during the early phase of an acute coronary 
syndrome. Consequently, clinical outcomes of patients 
with acute coronary syndrome undergoing percutaneous 
coronary intervention (PCI) have been significantly im­
proved and ischaemic risk has been reduced with the use 
of potent P2Y12 receptor inhibitors like prasugrel or 
ticagrelor, albeit at the expense of an increased bleeding 
risk.1–4 Current acute coronary syndrome guidelines recom­
mend potent P2Y12 receptor inhibitors for 1 year in patients 
with acute coronary syndrome managed by PCI.5 However, 
the greatest benefits of these potent drugs are seen early, 
when the risk of ischaemic complications is highest, while 
most haemorrhagic events with potent platelet inhibitors 
arise during chronic treatment.3,4 This rationale has fuelled 
interest in strategies of step­wise de­escalation6 using 
potent P2Y12 inhibitors only in the early phase of treatment, 
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and using the less potent clopidogrel during the chronic 
treatment course. However, to date, the evidence sup­
porting safety and efficacy and thereby justifying de­
escalation is limited and the few available data from 
smaller studies are conflicting.7,8 Despite the absence of 
unequivocal evidence, de­escalation of antiplatelet therapy 
after acute coronary syndrome is quite common in clinical 
practice8–11 and about 15–28% of patients with acute 
coronary syndrome9 are switched from potent to less 
potent treatment after discharge. This occurs for several 
reasons, including adverse bleeding events or non­
bleeding events, a perceived high bleeding risk, and 
economic issues favouring off­patent clopidogrel.1,9,11
Nevertheless, any de­escalation of antiplatelet therapy 
from a potent P2Y12 inhibitor to the less potent clopidogrel 
should account for large response variability of the latter12 
and the consequential issue of high on­treatment platelet 
reactivity (HPR), which exists in a substantial proportion 
of patients with acute coronary syndrome.13–15 Patients 
with HPR exhibit an increased risk for recurrent 
ischaemic events, including myocardial infarction and 
stent thrombosis.13–15 Hence, platelet function testing 
(PFT) could serve to make de­escalation safer by identi­
fying patients with HPR on clopidogrel, who might be 
exposed to an increased risk of thrombotic events due to 
insufficient P2Y12 inhibition and who should therefore 
continue potent P2Y12 inhibitors like prasugrel. Thus, we 
aimed to investigate the safety and efficacy of a PFT­guided 
early de­escalation of antiplatelet treatment compared 
with standard prasugrel therapy in patients with acute 
coronary syndrome undergoing PCI.
Methods
Study design and patients
The Testing Responsiveness To Platelet Inhibition On 
Chronic Antiplatelet Treatment For Acute Coronary 
Syn dromes (TROPICAL­ACS) trial was an investigator­
initiated, randomised, parallel­group, open­label, 
Research in context
Evidence before this study
International guidelines recommend potent platelet inhibition 
with prasugrel or ticagrelor in the first year after an acute 
coronary syndrome. Despite these recommendations, a regimen 
implying early de-escalation from potent antiplatelet agents to 
the less potent and off-patent clopidogrel is appealing both 
from a conceptual and economic perspective. We searched 
MEDLINE on July 1, 2017, for articles in English with the search 
terms “antiplatelet treatment de-escalation”, “switching 
antiplatelet therapy”, and “acute coronary syndrome 
guidelines”, and found only a few studies with a focus on clinical 
outcomes (TRANSLATE-ACS, SCOPE registry, TOPIC trial). Data 
from the TRANSLATE-ACS registry showed that de-escalation is 
common clinical practice with up to 28% of patients with acute 
coronary syndrome switching from potent platelet inhibition 
down to clopidogrel within the first year post discharge on their 
own or their physician’s initiative. The reasons for de-escalation 
most predominantly include adverse events and issues with 
reimbursement or availability of potent platelet inhibitors. 
However, to date, evidence supporting safety and efficacy and 
thereby justifying de-escalation is lacking and even conflicting. 
While data from a single registry (SCOPE) pointed towards 
potential hazards of de-escalating treatment after acute 
coronary syndrome, a smaller single-centre randomised trial 
(TOPIC) favoured uniform de-escalation of treatment in event-
free patients with acute coronary syndrome at 1 month after 
percutaneous coronary intervention, mainly driven by a 
reduction of Bleeding Academic Research Consortium (BARC) 
grade 2 or higher bleeding in patients receiving de-escalated 
antiplatelet treatment.
Added value of this study
To the best of our knowledge, TROPICAL-ACS is the first 
randomised trial to investigate a strategy of early and guided 
de-escalation of P2Y12 inhibition in patients with acute coronary 
syndrome. The trial population represents a high-risk cohort of 
biomarker-positive patients with acute coronary syndrome 
including more than 1400 patients with ST-elevation myocardial 
infarction. De-escalation guided by platelet function testing (PFT) 
ensured sufficient platelet inhibition in all patients with acute 
coronary syndrome in the experimental arm, with about 60% of 
patients continuing on clopidogrel treatment and 40% of 
patients requiring escalation back to prasugrel. By showing 
non-inferiority of PFT-guided de-escalation compared with a 
standard of potent platelet inhibition for 12 months, our trial 
provides important evidence justifying tailored de-escalation as 
an alternative strategy in patients with acute coronary syndrome 
after coronary stenting. Study results are applicable to all 
scenarios of de-escalation, regardless of whether the need to 
de-escalate arises from clinical or economic issues. PFT results can 
help to justify de-escalation in clopidogrel responders, while they 
might also help to overcome budgetary issues for patients that 
would require escalation back to prasugrel.
Implications of all the available evidence
Based on all the available evidence, uniform and potent platelet 
inhibition in patients with acute coronary syndrome probably 
remains standard of care, because TROPICAL-ACS did not show 
superiority of de-escalation. Notwithstanding, alternative 
treatment concepts are desired for a significant proportion of 
patients in clinical practice. Our trial now supports the safety 
and efficacy of an early and guided de-escalation of platelet 
inhibition in patients with acute coronary syndrome as an 
alternative strategy that can be followed whenever necessary 
for medical or socioeconomic reasons. The regimen of guided 
treatment seems also practical beyond the framework of a 
randomised controlled trial, because patients in many countries 
worldwide typically have planned outpatient visits within the 
first weeks after an acute coronary syndrome.
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assessor­blinded, multicentre trial that was done at 
33 European sites (two in Austria, 20 in Germany, 
seven in Hungary, and four in Poland) and had an 
academic sponsor (Klinikum der Universität München). 
Patients were eligible if they had biomarker­positive 
acute coronary syndrome with a successful PCI (defined 
as a post­PCI diameter stenosis <20% and thrombolysis 
in myocardial infarction [TIMI] flow ≥2), and planned 
treatment of prasugrel for 12 months after the procedure. 
The appendix (p 2) lists all inclusion and exclusion 
criteria; the study protocol with further details has been 
published previously.16
Patients provided written informed consent. An inde­
pendent data safety monitoring board (DSMB) over­
saw the trial and had full access to unblinded data. 
Study monitoring for all patients was done by an ex­
ternal service provider (Münchner Studienzentrum, 
MSZ, Munich, Germany). The institutional ethics com­
mittee of each participating site, as well as the competent 
national agencies approved the trial. The study was 
conducted in accordance with the principles of the 
Declaration of Helsinki.
Randomisation and masking
Using an internet­based randomisation procedure with a 
computer­generated block randomisation with strati­
fication across study sites, patients with acute coronary 
syndrome were randomly assigned before planned 
discharge in a 1:1 fashion to the two study groups of either 
PFT­guided de­escalation or control group. Patients were 
considered enrolled in the study and eligible for the final 
intention­to­treat analysis at the time of randomisation. 
Figure 1 summarises the study flow of the TROPICAL­ACS 
study. Patients in the control group received a standard 
care of 12 month prasugrel treatment at a dose of 10 mg 
or 5 mg according to the label and the current guideline 
recommendations.5,17 Patients in the de­escalation group 
received a post­discharge treatment, consisting of 1 week 
prasugrel treatment (10 mg or 5 mg per day) followed by 
1 week of clopidogrel treatment (75 mg per day) and a 
platelet function measurement (on clopidogrel) 2 weeks 
after hospital discharge (PFT­guided de­escalation group). 
Based on PFT results in the guided de­escalation group, 
patients were either switched back to prasugrel, when a 
status of HPR with insufficient platelet inhibition was 
detected, whereas patients with sufficient platelet 
inhibition (no HPR) continued with clopidogrel.
Study group­related treatment was planned to start on 
the day after discharge and study drugs for the first 
14 days post discharge were packed and provided by the 
pharmacy department of the Klinikum der Universität 
München (Munich, Germany). We deemed this necessary 
to guarantee an exact intake of tablets during a time 
frame covering the switch of treatment in the guided de­
escalation group. For both groups, three extra tablets 
(provisional medication) were included in the box for 
week 2 to ensure flexibility regarding the timing of the 
first follow­up visit out to day 17. Treatment after day 14 
post discharge until 12 months was planned according to 
the assigned randomisation and HPR status in the 
guided de­escalation group and was prescribed by the 
patient’s primary care physician in both study groups. 
Further details on randomisation procedures and study 
drugs were published previously.16
Procedures
2 weeks after discharge from the primary care hospital, 
where the index PCI was done, all patients had an 
outpatient visit. In addition, patients were contacted by 
phone call at 30 days, 6 months, and 12 months after 
randomisation. These calls were made to explore study 
endpoints and adverse events and to assess adherence to 
the assigned antiplatelet therapy using a study­specific 
designed standardised questionnaire. In case of a 
suspected clinical event all source data were collected to 
allow for precise event adjudication by the event 
adjudication committee.
For the on­site follow­up visit, participants from both 
study groups underwent planned and prescheduled blood 
sampling for PFT under steady­state conditions. The 
Multiplate analyser (Roche Diagnostics, Rotkreuz, 
Switzerland) was used for testing. Details of this method 
and its predictive value have been published prev­
iously.13,14,16 A status of HPR was defined based on the 
results of previous studies and the consensus documents 
of the Working Group on HPR as an adenosine 
diphosphate test aggregation value of 46 units or higher 
on the Multiplate analyser.13,14 In the control group, testing 
was done only for obser vational purposes and results did 
not affect drug selection or dosing. In the guided de­
escalation group, testing results determined the further 
course of treatment: patients with HPR were immediately 
switched back to prasugrel, while those without HPR 
continued on clopi dogrel (figure 1).
Outcomes
The primary endpoint was a combined ischaemic and 
bleeding endpoint (net clinical benefit), which was the 
composite of death from cardiovascular causes (all deaths 
were assumed cardiovascular in nature unless a non­
cardiovascular cause could be clearly provided), myo­
cardial infarction (defined according to the 3rd universal 
definition of myocardial infarction18), stroke, and bleeding 
grade 2 or higher defined according to Bleeding Academic 
Research Consortium (BARC) criteria19 at 12 months after 
randomisation. The key secondary endpoint was defined 
as BARC class 2 or higher bleeding events at 12 months. 
Further secondary endpoints included the ischaemic 
components (com bined and singular) of the primary 
endpoint (cardio vascular death, myocardial infarction, 
and stroke), stent thrombosis defined according to 
Academic Research Consortium (ARC) criteria,20 the 
incidence of death from any cause, and urgent ischaemia­
driven revascularisation at 12 months. With respect to 
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bleeding events, all reported bleedings were assessed 
and reported according to BARC classification (BARC 
types 1–5). An independent event adjudication committee 
masked to treatment assignment adjudicated all sus­
pected clinical events.
Statistical analysis
The study was designed to show non­inferiority for the 
guided de­escalation group versus the control group 
regarding the primary composite endpoint. Considering 
the results of a landmark analysis from the TRITON­
TIMI 38 trial,3 based on the incidence of early versus late 
major bleeding events3 and based on the incidence of 
BARC 2 or higher bleeding complications in a PCI 
cohort,21 the incidence of the primary endpoint of this 
study was assumed to be 10·5% in the control group. A 
non­inferiority margin of 30% was estimated, which is in 
accordance with non­inferiority margins used in contem­
porary trials of antithrombotic treatment in cardiovascular 
diseases.22,23 Sample size calculations (nQuery Advisory, 
Statistical Solutions, Farmer’s Cross, Cork, Ireland) were 
done based on a one­sided type 1 error of 5% and a 
power of 80%. For the primary endpoint assumptions, 
1172 patients in each group were needed. Assuming an 
incidence of BARC 2 or higher bleeding in the control 
group of 4·9% and an expected reduction of BARC 2 or 
higher bleeding by 45% in the de­escalation group, 
1179 patients per group would be required to show 
superiority (based on two­sided type 1 error of 5% and a 
power of 80% for the key secondary endpoint (BARC 2 or 
higher bleeding). To compensate for losses to follow­up 
and to be powered for the primary and secondary 
endpoint assessment the enrolment of a total of 
2600 patients (1300 patients per group) was planned. All 
analyses were done on an intention­to­treat basis. In 
addition, per­protocol analyses were done. Differences in 
endpoints were analysed in Cox­regression models for 
survival analysis. In all cases of the use of the Cox 
proportional hazards model, the proportional hazards 
assumption was met. Kaplan­Meier plots were generated 
to visualise the risk of outcome events in both groups. 
Binary and other categorical variables were compared 
using Fisher’s exact test and χ² test, respectively, for 
continuous data two­sided unpaired Wilcoxon test or 
Student’s t test were used as appropriate. Data were 
analysed with R version 3.3.0.
Role of the funding source
The funders of this study had no role in study design, 
collection of data and data analysis, or writing of the 
manuscript. DS and SM had full access to the data and 
take full responsibility for the decision to submit for 
publication.
This study is registered with ClinicalTrials.gov, number 
NCT01959451, and EudraCT, 2013­001636­22.
Figure 1: Study design and groups
The figure shows the control group and the experimental group with guided de-escalation of antiplatelet treatment. Patients were randomly assigned (1:1) after 
PCI and directly before planned discharge from hospital. On-treatment platelet reactivity was measured in both study groups. In the control group, on-prasugrel 
testing results had no effect on further treatment, which was prasugrel for all patients. Based on the testing results in the guided de-escalation group (on 
clopi dogrel treatment), the further treatment was determined at day 14 post discharge. Protocol-mandated treatment required clopidogrel in no-HPR patients and 
a switch back to prasugrel in HPR patients. PCI=percutaneous coronary intervention. HPR=high on-treatment platelet reactivity. R*=randomisation. DAPT=dual 
antiplatelet therapy.
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biomarker-positive
acute coronary
syndromes and
successful PCI
14 days
prasugrel
11·5 months
prasugrel
11·5 months
prasugrel
11·5 months
clopidogrel
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(PFT-guided)
Figure 2: Trial profile
2619 patients with acute coronary syndromes 
 randomly assigned 
2610 patients with acute coronary syndromes 
 assigned to study groups
53 were lost to follow-up
 26 at day 14
 4 at day 30
 13 at 6 months
 10 at 12 months
57 were lost to follow-up
 18 at day 14
 8 at day 30
 14 at 6 months
 17 at 12 months
1304 assigned to guided de-escalation group 1306 assigned to control group
1304 were included in the intention-to-treat analysis 1306 were included in the intention-to-treat analysis
9 excluded due to randomisation failures
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Results
Between Dec 2, 2013, and May 20, 2016, 2610 eligible 
patients with acute coronary syndrome were randomly 
assigned at 33 European PCI sites (figure 2). These 
patients constitute the intention­to­treat population, in 
which 1306 patients were randomly assigned to the 
control group and 1304 patients to the guided de­
escalation group. Mean age of patients was 59 years 
(SD 10) and 558 (21%) were women. 1453 (56%) patients 
presented with ST­elevation myocardial infarction 
(STEMI). Table 1 summarises the baseline characteristics 
of the study cohort and table 2 provides an overview of 
procedural characteristics of the index PCI.
For the pre­scheduled follow­up visit at 2 weeks after 
hospital discharge the follow­up rate was 98% in the 
guided de­escalation group and 99% in the control group. 
In the guided de­escalation group, a status of HPR was 
noted in 511 patients (39% of the intention­to­treat 
population). In line with the protocol, 506 (99%) of the 
Control group
(n=1306)
Guided de-escalation 
group  (n=1304)
Cause of PCI
STEMI 722 (55%) 731 (56%)
NSTEMI 584 (45%) 573 (44%)
Access site
Brachial 3 (<1%) 0
Femoral 541 (41%) 523 (40%)
Radial 762 (58%) 781 (60%)
Number of diseased coronary vessels
1 682 (52%) 659 (51%)
2 345 (26%) 359 (28%)
3 279 (21%) 286 (22%)
Anticoagulant agent used for PCI
Bivalirudin 55 (4%) 54 (4%)
Low molecular 
weight heparin
70 (5%) 72 (6%)
Unfractionated heparin 1181 (90%) 1178 (90%)
Use of glycoprotein IIb/IIIa 
antagonist
247 (19%) 244 (19%)
TIMI flow grade before PCI
0 512 (39%) 511 (39%)
1 171 (13%) 173 (13%)
2 302 (23%) 321 (25%)
3 321 (25%) 299 (23%)
Coronary vessels treated
Left main 12 (1%) 29 (2%)
Left anterior descending 556 (43%) 562 (43% )
Left circumflex 253 (19%) 266 (20%)
Right coronary artery 450 (35%) 433 (33%)
Coronary bypass graft 35 (3%) 14 (1%)
AHA/ACC classification of lesions
A 155 (12%) 161 (12%)
B1 425 (33%) 434 (33%)
B2 340 (26%) 327 (25%)
C 386 (30%) 382 (29%)
Ostial lesion 98 (8%) 97 (7%)
Bifurcation lesion 195 (15%) 204 (16%)
Stent type
DES 1002 (77%) 1003 (77%)
BMS 208 (16%) 224 (17%)
BVS 83 (6%) 68 (5%)
None (PTCA only) 13 (1%) 9 (1%)
TIMI flow grade after PCI
2 38 (3%) 38 (3%)
3 1268 (97%) 1266 (97%)
Data are n (%). STEMI=ST-segment elevation myocardial infarction. 
NSTEMI=non-ST-segment elevation myocardial infarction. PCI=percutaneous 
coronary intervention. TIMI=thrombolysis in myocardial infarction. 
AHA=American Heart Association. ACC=American College of Cardiology. 
DES=drug-eluting stent. BMS=bare metal stent. BVS=bioresorbable vascular 
scaffold. PTCA=percutaneous transluminal coronary angioplasty. 
Table 2: Angiographic and procedural characteristics
Control group 
(n=1306)
Guided de-escalation 
group (n=1304)
Age (years) 58·5 (10·2) 59·0 (10·1)
Men 283 (22%) 275 (21%)
Body-mass index (kg/m2) 28·4 (5·0) 28·1 (4·5)
White 1295 (99%) 1295 (99%)
Previous percutaneous 
coronary intervention
186 (14%) 173 (13%)
Previous coronary 
artery bypass surgery
46 (4%) 39 (3%)
Previous myocardial 
infarction
153 (12%) 140 (11%)
History of peripheral artery 
occlusive disease
39 (3%) 46 (4%)
History of coronary 
artery disease
204 (16%) 175 (13%)
Renal insufficiency 34 (3%) 33 (3%)
Diabetes mellitus 287 (22%) 240 (18%)
Current smoker 591 (45%) 591 (45%)
Arterial hypertension 806 (62%) 793 (61%)
Hyperlipidaemia 529 (41%) 546 (42%)
Family history of 
coronary artery disease
466 (36%) 419 (32%)
Haemoglobin (g/dL) 14·2 (1·6) 14·3 (1·6)
Creatinine (mg/dL) 0·9 (0.2) 0·9 (0.3)
Medication at admission
Aspirin 343 (26%) 303 (23%)
ADP receptor antagonist 76 (6%) 71 (5%)
Beta blocker 368 (28%) 378 (29%)
ACE inhibitor 341 (26%) 357 (27%)
Angiotensin1 receptor 
antagonist
161 (12%) 173 (13%)
Calcium antagonist 166 (13%) 178 (14%)
Proton-pump inhibitor 175 (13%) 174 (13%)
Statin treatment 298 (23%) 286 (22%)
Data are n (%) or mean (SD). ADP=adenosine diphosphate. 
ACE=angiotensin-converting-enzyme.
Table 1: Baseline characteristics of the intention-to-treat population
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511 patients were switched back from clopidogrel to 
prasugrel, while only five patients with HPR continued 
clopidogrel based on an individual decision of the 
treating physician at the follow­up visit. In the control 
group, a status of HPR was found in 188 patients (14% of 
the intention­to­treat population). Adherence to the 
assigned P2Y12 inhibitor therapy was repeatedly assessed 
throughout the study in all patients. During the study 
period of 12 months, adherence to the protocol­mandated 
treatment was high with a rate of 94·2% in the control 
group and 94·4% in the guided de­escalation group. Use 
of low­dose (5 mg per day) instead of standard dose 
prasugrel (10 mg per day) for study drug treatment was 
low (4·0% in guided de­escalation group vs 4·2% in 
control group) and did not differ between the study 
groups (p=0·88). During the 1­year study period, 
43 patients (2%) withdrew consent and 110 (4%) were lost 
to follow­up (figure 2).
At 1 year, the combined primary endpoint occurred in 
95 patients (7%) in the guided de­escalation group and 
in 118 patients (9%) in the control group 
(pnon­inferiority=0·0004; HR 0·81 [95% CI 0·62–1·06], 
psuperiority=0·12; table 3; figure 3A). The ischaemic 
components of the primary endpoint (cardiovascular 
death, myocardial infarction, and stroke) occurred in 
32 patients (3%) in the guided de­escalation group and 
in 42 patients (3%) in the control group (HR 0·77 
[95% CI 0·48–1·21]; p=0·25; figure 3C), indicating that 
early de­escalation did not result in an increased risk of 
cardiovascular death, myocardial infarction, or stroke 
(pnon­inferiority=0·0115). Table 3 sum marises relevant 
outcome data for all individual components of the 
combined ischaemic endpoint. No significant 
differences were observed for any of the ischaemic 
components of the primary endpoint (p≥0·22) as well as 
for the rate of urgent revascularisation (p=0·13). All­
cause mortality at 1 year was 1% (12 events) in the 
control group versus 1% (11 events) in the guided de­
escalation group (p=0·85). The cumulative incidence of 
definite stent thrombosis was low with two events (<1%) 
in the guided de­escalation group versus three events 
(<1%) in the control group (HR 0·67 [95% CI 0·11–4·03]; 
p=0·66).
The incidence of the key secondary endpoint of BARC 2 
or higher bleedings was 5% (64 events) in the guided de­
escalation group versus 6% (79 events) in the control 
group (HR 0·82 [95% CI 0·59–1·13]; p=0·23; figure 3B). 
The cumulative incidence of all bleeding events (BARC 
class 1 to 5) was 9% (114 events) in the guided de­
escalation group versus 11% (137 events) in the control 
group (HR 0·83 [95% CI 0·65–1·06]; p=0·14; figure 3D). 
Table 3 summarises all bleeding events according to 
BARC types (1 to 5) across groups. Per­protocol analyses 
yielded similar results to the intention­to­treat analyses 
for the primary study endpoint (HR 0·84 [95% CI 
0·64–1·19]; pnon­inferiority=0·0013 for guided de­escalation 
vs control group) and for the key secondary endpoint of 
BARC 2 or higher bleedings (HR 0·81 [95% CI 
0·58–1·17]; p=0·24 for guided de­escalation vs control 
group) of the study.
Relevant clinical variables like clinical presentation 
(STEMI vs non­ST elevation myocardial infarction 
[NSTEMI]), age, sex, and status for diabetes were subject 
to post­hoc subgroup analyses for the primary endpoint. 
For study group comparisons, patients with STEMI 
(HR 0·54 [95% CI 0·35–0·83]; p=0·004; pinteraction=0·0116) 
and younger (age ≤70 years) patients (0·70 [0·51–0·96]; 
p=0·0270; pinteraction for categorical model =0·11, pinteraction for 
continuous model =0·0229) showed significant 
differences favouring guided de­escalation. Figure 4 
shows the results of relevant subgroups and their 
outcomes with respect to the study group. Further 
analyses of all control group patients versus patients 
treated with clopidogrel from the guided de­escalation 
group and on patients treated with prasugrel versus those 
Control group 
(n=1306)
Guided 
de-escalation 
group 
(n=1304)
Hazard ratio 
(95% CI)
p value
Net clinical benefit
Primary endpoint (cardiovascular 
death, myocardial infarction, 
stroke, bleeding BARC ≥2)
118 (9%) 95 (7%) 0·81 (0·62–1·06) pnon-inf =0·0004; 
psup =0·12
Combined ischaemic events 
(cardiovascular death, 
myocardial infarction, stroke) 
and all bleeds 
(BARC bleeding 1–5)
175 (13%) 143 (11%) 0·81 (0·65–1·01) 0·06
Ischaemic events
Combined ischaemic events 
(cardiovascular death, 
myocardial infarction, stroke)
42 (3%) 32 (3%) 0·77 (0·48–1·21) pnon-inf =0·0115
Cardiovascular death 9 (1%) 7 (1%) 0·78 (0·29–2·10) 0·63
Myocardial infarction 28 (2%) 24 (2%) 0·86 (0·50–1·49) 0·59
Stroke 7 (1%) 3 (<1%) 0·43 (0·11–1·67) 0·22
Stent thrombosis (definite) 3 (<1%) 2 (<1%) 0·67 (0·11–4·03) 0·66
All-cause mortality 12 (1%) 11 (1%) 0·92 (0·41–2·10) 0·85
Urgent revascularisation 29 (2%) 40 (3%) 1·45 (0·89–2·34) 0·13
Bleeding events
Key secondary endpoint (BARC 
bleeding ≥2)
79 (6%) 64 (5%) 0·82 (0·59–1·13) 0·23
BARC type 1 or 2 119 (9%) 98 (8%) 0·82 (0·63–1·07) 0·15
BARC type 3 or 5 20 (2%) 17 (1%) 0·85 (0·45–1·63) 0·63
Any BARC bleeding 137 (11%) 114 (9%) 0·83 (0·65–1·06) 0·14
Bleeding events
BARC type 1 64 (5%) 52 (4%) 0·81 (0·56–1·17) 0·26
BARC type 2 61 (5%) 47 (4%) 0·77 (0·53–1·13) 0·19
BARC type 3 19 (2%) 17 (1%) 0·90 (0·47–1·73) 0·75
BARC type 4 1 (<1%) 2 (<1%) 2·02 (0·18–22·20) 0·57
BARC type 5 1 (<1%) 0 .. 0·89
Data are n (%). p values presented are for superiority comparisons unless otherwise stated. BARC=Bleeding Academic 
Research Consortium. pnon-inf=p value for non-inferiority. psup=p value for superiority.
Table 3: Clinical outcomes at 12 months’ follow-up
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treated with clopidogrel (as­treated analysis) are shown in 
the appendix (pp 3–4).
Discussion
De­escalation of antiplatelet treatment after an acute 
coronary syndrome is conceptually appealing and 
frequently practised in real­world scenarios.6,8–11,24–26 
Nevertheless, there is little evidence until now to justify 
switching regimens. TROPICAL­ACS is currently the 
only trial investigating a concept of guided de­escalation 
of P2Y12 inhibition in an all­comers cohort of patients 
with acute coronary syndrome. Key findings from this 
study are that a stage­adapted antiplatelet treatment 
strategy with initial potent platelet inhibition using 
prasugrel, followed by guided dual antiplatelet treatment 
(DAPT) de­escalation to clopidogrel proved to be feasible 
and non­inferior to conventional 12­month prasugrel 
therapy. In particular, the rate and distribution of 
ischaemic events were not increased with guided DAPT 
de­escalation. Hence, this study identifies guided DAPT 
de­escalation as an alternative strategy in patients with 
acute coronary syndrome that are deemed unsuitable for 
maintained potent platelet inhibition for whatever 
medical or socioeconomic reasons.9
Several further observations are worth mentioning. 
First, by contrast with previous studies investigating 
concepts of uniform de­escalation,7,8 we used individ­
ualised PFT­guided de­escalation in this study. Landmark 
data3,4 from PLATO and TRITON­TIMI 38 trials showed 
that even though protection from recurrent ischaemia 
with potent agents was most prominent during the acute 
phase, it persisted throughout chronic treatment out to 
12 months after an acute coronary syndrome. Hence, PFT 
guidance of de­escalation was applied to guarantee 
sufficient platelet inhibition in all patients with acute 
coronary syndrome during their chronic course of 
treatment. Second, adherence to per­protocol DAPT was 
higher than in many other recent trials of acute coronary 
syndrome1,7,10 and ischaemic risk was low in both study 
groups. These observations could be related to the fact 
that drug treatment was monitored in all patients enrolled 
into our trial, which potentially had beneficial effects on 
Figure 3: Kaplan-Meier curves for the primary endpoint (net clinical benefit; A), the key secondary endpoint (BARC 2 or higher bleeding; B), the combined ischaemic endpoint (C), and all 
bleeding events (BARC class 1–5; D) at 12 months’ follow-up
BARC=Bleeding Academic Research Consortium. HR=hazard ratio.
Number at risk
Control group
De-escalation
group
0 60 120 180 240 300 360
1306
1304
1238
1234
1220
1213
1190
1189
1132
1129
1124
1124
924
942
9·0%
7·3%
6·1%
4·9%
0
2
4
6
8
10
12
Pr
op
or
tio
n 
of
 p
at
ie
nt
s w
ho
 a
ch
ie
ve
d
co
m
bi
ne
d 
isc
ha
em
ic 
ev
en
ts
 o
r B
AR
C
≥2
 b
le
ed
in
g 
(p
rim
ar
y 
en
dp
oi
nt
; %
)
A
Control group
Guided de-escalation group
HR 0·81 (95% CI 0·62–1·06)
pnon-inferiority=0·0004
psuperiority=0·12
0 60 120 180 240 300 360
1306
1304
1253
1244
1124
1226
1214
1205
1158
1148
1152
1145
950
960
0
2
4
6
8
10
12
Pr
op
or
tio
n 
of
 p
at
ie
nt
s w
ho
 a
ch
ie
ve
d 
BA
RC
≥2
 b
le
ed
in
g 
(k
ey
 se
co
nd
ar
y 
en
dp
oi
nt
; %
)
B
HR 0·82 (95% CI 0·59–1·13)
p=0·23
Number at risk
Control group
De-escalation
group
0 60 120 180 240 300 360
1306
1304
1257
1255
1250
1249
1233
1234
1188
1179
1183
1176
970
988
3·2%
2·5%
10·5%
8·7%
Follow-up (days)
0
2
4
6
8
10
12
Pr
op
or
tio
n 
of
 p
at
ie
nt
s w
ho
 a
ch
ie
ve
d
co
m
bi
ne
d 
isc
ha
em
ic 
ev
en
ts
 (%
)
C
HR 0·77 (95% CI 0·48–1·21)
pnon-inferiority=0·0115
0 60 120 180 240 300 360
1306
1304
1211
1219
1196
1197
1167
1170
1105
1109
1099
1102
900
920
Follow-up (days)
0
2
4
6
8
10
12
Pr
op
or
tio
n 
of
 p
at
ie
nt
s w
ho
 h
ad
an
y 
bl
ee
di
ng
 e
ve
nt
s (
%
)
D
HR 0·83 (95% CI 0·65–1·06)
p=0·14 
Articles
8 www.thelancet.com   Published online August 27, 2017   http://dx.doi.org/10.1016/S0140-6736(17)32155-4
patient compliance. Third, high drug adherence and 
follow­up rates within this study proved the feasibility of 
guided de­escalation as early as 1 week after patient’s 
discharge. DAPT de­escalation seems clinically most 
relevant when applied early, considering that adverse 
events, including side­effects and bleeds, occur over time 
during maintenance therapy. Nevertheless, it seems 
reasonable to extrapolate from this study that de­
escalation would also be feasible and safe at later stages 
during chronic antiplatelet treatment. Further on, the rate 
of ischaemic events was lower in this study than in 
previous trials, including TRITON­TIMI 38 and PLATO.1,2 
It must be emphasised that randomisation in our trial 
was done before discharge and hence several days 
after PCI. Thus, early and peri­procedural events that 
dominated the overall event rates of previous studies1,2 
were not included in our trial. This together with the 
increased safety of contemporary PCI with a high rate of 
radial access and use of latest generation drug­eluting 
stents (eg, everolimus­eluting or zotarolimus­eluting 
stents) are likely explanations for the lower risk of 
ischaemic events in our trial.
Previous trials addressing concepts of de­escalation of 
antiplatelet treatment are limited and have yielded 
somewhat conflicting findings. Observational data from 
the SCOPE8 registry enrolling 1363 patients with acute 
coronary syndrome showed that de­escalation from potent 
antiplatelet inhibitors to clopidogrel was independently 
associated with adverse events during chronic DAPT. By 
contrast, the recent TOPIC trial7 reported that a switch over 
from ticagrelor or prasugrel to clopidogrel 1 month 
after PCI for acute coronary syndrome reduced bleed­
ing complications. However, TOPIC differs essentially 
from this study in various aspects: first, primary end­
point selection (composite of cardiovascular death, un­
planned hospital admission leading to urgent coronary 
revascularisation, stroke, and bleeding episodes as defined 
by the BARC type ≥2) allowing for a smaller sample size to 
show superiority (645 patients in TOPIC vs 2610 patients in 
TROPICAL­ACS); second, the monocentric study design 
in TOPIC; third, a moderate adherence (75%) to treatment 
in the control group of TOPIC; fourth, TOPIC did not 
specifically report important ischaemic endpoints like 
myocardial infarction or stent thrombosis, limiting the 
conclusions that can be made regarding safety aspects of 
de­escalation; and most importantly, fifth, TOPIC used 
uniform de­escalation switching all patients in the de­
escalation arm from an established potent P2Y12 inhibitor 
to the less potent clopidogrel. By contrast, our study 
accounts for the substantial response variability of 
clopidogrel12,14,15 and considers the persistent anti­ischaemic 
potential of sufficient platelet inhibition seen during 
the chronic treatment phase.1,2 This is achieved by 
imple mentation of drug­response testing precluding de­
escalation in patients with HPR, carrying a higher risk of 
thrombotic events in a background of insufficient P2Y12 
inhibitor therapy.14,15 Findings from this study show that 
PFT­tailored de­escalation is safe, because none of the 
ischaemic endpoints—alone or in combination—tended 
to be higher in the guided de­escalation group than in the 
control group. We also did not observe any clustering of 
thrombotic events during the early phase of treatment 
after discharge, where antiplatelet drugs were switched per 
protocol in the guided de­escalation group.
Besides recurrent ischaemia, bleeding complications 
are among the most frequent adverse events after PCI, 
both during the acute and even more so during the 
maintenance phase of treatment.3,4 We observed 
numerically more events across all BARC classes in the 
control group than in the guided de­escalation group. 
However, these differences did not reach a level of 
statistical significance and were most pronounced for 
minimal and minor bleeds, while we observed no 
relevant reduction in BARC 3–5 bleeding in the guided 
de­escalation group. However, even minor bleeds might 
have important effects on treatment compliance and 
health­care costs.27–29 The relative risk reductions observed 
for bleeding risk in this study are similar to the 
differences observed in prasugrel versus clopidogrel 
study groups in the TRITON­TIMI trial.2 Nevertheless, 
the overall reduction in bleeding risk by de­escalation 
was smaller than expected, which might at least in part 
be due to the fact that about 40% of patients in the guided 
de­escalation group showed HPR on clopidogrel and 
continued prasugrel maintenance treatment.
Even though this study uses PFT to back up de­
escalation in a cohort of patients in which potent platelet 
inhibition is established and recommended, it should 
not be considered primarily a PFT study. Nevertheless, 
our trial needs to be discussed against the background 
of previous studies using PFT to tailor DAPT. 
ADAPT­DES15 and large meta­analyses14 have confirmed 
the predictive value of PFT for ischaemic and bleeding 
events after PCI. However, subsequent randomised 
Figure 4: Subgroup analyses
Subgroup analyses of the primary composite endpoint (net clinical benefit) in relevant subgroups of the study 
cohort (clinical presentation: STEMI/NSTEMI, sex, age, and diabetes). pinteraction represents the likelihood of 
interaction between the variable and the treatment strategy (platelet function testing-guided de-escalation 
vs uniform prasugrel treatment). ACS=acute coronary syndrome. HR=hazard ratio. STEMI=ST-segment elevation 
myocardial infarction. NSTEMI=non-ST-segment elevation myocardial infarction.
HR (95% CI) p interaction
ACS presentation
 STEMI (n=1453)
 NSTEMI (n=1157)
Sex
 Men (n=2052)
 Women (n=558)
Age
 >70 years (n=370)
 ≤70 years (n=2240)
Diabetes
 Yes (n=527)
 No (n=2083)
Overall
 0·0116
 0·60
 0·11
 0·10
 0·54 (0·35–0·83)
 1·10 (0·77–1·58)
 0·78 (0·57–1·06)
 0·92 (0·53–1·62)
 1·17 (0·69–2·01)
 0·70 (0·51–0·96)
 1·17 (0·71–1·93)
 0·71 (0·52–0·99)
 0·81 (0·62–1·06)
1·000·500·33 2·001·500·75
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trials implementing PFT for guidance of antiplatelet 
therapy failed to show a positive effect of testing on 
patient outcomes. Yet, the concepts of tailored treatment 
tested in previous trials substantially differ from the 
approach of guided de­escalation investigated in this 
study. Earlier trials aimed to test PFT­guided escalation 
rather than de­escalation of DAPT focusing pre­
dominantly30,31 or exclusively32 on low­risk elective PCI 
patients. The recent ANTARCTIC trial33 is the only 
previous trial using PFT to tailor DAPT in a dedicated 
acute coronary syndrome cohort. However, there are 
substantial differences in study design between 
ANTARCTIC and this study: ANTARCTIC randomly 
assigned patients with acute coronary syndrome who 
were aged 75 years or older to receive oral prasugrel 
5 mg daily with or without dose or drug adjustment for 
escalation or de­escalation depending on platelet 
function monitoring. In essence, ANTARCTIC 
compared the effect of prasugrel 5 mg to a regimen in 
which low­dose prasugrel was replaced by clopidogrel 
75 mg in less than half of patients. This is a limitation of 
ANTARCTIC, because superiority of low dose prasugrel 
(5 mg) compared with clopidogrel 75 mg with respect to 
clinical outcomes has never been confirmed. Hence, 
TROPICAL­ACS is the only trial designed to test PFT­
guided de­escalation of standard dose prasugrel to 
clopidogrel in all­comers patients with acute coronary 
syndrome. Generally, standardised platelet function 
assays are practical and have already been implemented 
into clinical routine.34 From an economic point of view, 
costs for PFT are marginal, while cost savings when 
using off­patent clopidogrel instead of potent platelet 
inhibitors can be substantial.29
Our study population was characterised by a high 
proportion (>50%) of high­risk STEMI patients. STEMI 
patients derived a net clinical benefit from guided DAPT 
de­escalation. This is not contradictory to observations 
made in TRITON­TIMI,35 where STEMI patients showed 
the greatest benefit of potent inhibition very early after 
PCI, a time frame where also in TROPICAL­ACS both 
groups received uniform prasugrel treatment. One 
underlying reason for the positive interaction observed 
for STEMI patients might be related to the fact that this 
cohort is characterised by less comorbidities and a lower 
frequency of multivessel disease when compared with 
NSTEMI patients.36 In fact, the idea of tailored de­
escalation in STEMI patients was brought up years ago,37 
based on the results of the STEMI subgroup in TRITON­
TIMI.35 Our study tackles this hypothesis and suggests 
that STEMI patients could be good candidates for DAPT 
de­escalation, whenever this is deemed necessary. In 
addition, younger patients (≤70 years), constituting 
86% of the entire study population, also showed 
favourable outcomes with guided de­escalation. 
Nevertheless, subgroup analyses should be understood 
as descriptive and hypothesis generating. Definite 
answers on what subgroups derive a significant clinical 
benefit from guided de­escalation would require even 
larger clinical trials powered to show superiority.
We acknowledge limitations related to our clinical 
trial. The non­inferiority margin of 30% chosen for our 
study can be considered as a potential limitation. 
However, in post­hoc analyses non­inferiority for the 
primary endpoint was even maintained with a smaller 
non­inferiority margin of 10% (pnon­inferiority=0·0117). This, 
together with the fact that both ischaemic as well as 
bleeding event rates if any were numerically lower, but 
not higher with guided de­escalation compared with 
standard treatment, justifies implementation of guided 
de­escalation as an alternative treatment strategy into 
clinical practice. Our protocol mandated for choosing 
prasugrel. Thus, to what extent our findings can be 
extrapolated to ticagrelor remains unclear. Nevertheless, 
prasugrel and ticagrelor have very similar P2Y12 
inhibitory effects38 and a randomised study comparing 
the two drugs in patients with acute coronary syndrome 
showed similar efficacy and safety outcomes.10 This 
suggests that our findings could indeed apply to patients 
with acute coronary syndrome treated with ticagrelor. 
TROPICAL­ACS was planned as an all­comers trial and 
did not preferentially enrol patients susceptible to 
bleeding complications, even though they represent 
potential and excellent candidates for PFT guided de­
escalation and are more likely to de­escalate DAPT post­
discharge based on large observational registries.9 
However, patients susceptible to bleeding complications 
were also excluded from the PLATO and TRITON­TIMI 
38 trials.1,2 Hence, whether these patients derive a net 
clinical benefit from potent platelet inhibitors in the first 
place is unclear. As a consequence, enrolment of patients 
susceptible to bleeding into a trial using prasugrel in 
one study arm is probably limited by preferential upfront 
use of clopidogrel in these patients and the reduced 
adherence to potent platelet inhibition. Finally, further 
limitations of our trial are the open­label design, the 
exclusion of patients with a history of stroke, and the 
proportion of patients lost to follow­up, which was 4% in 
both study groups.
In conclusion, a guided de­escalation of antiplatelet 
treatment was non­inferior to standard treatment with 
prasugrel in terms of net clinical benefit. A concept of 
guided de­escalation was characterised by a high rate of 
adherence to treatment and proved feasible in clinical 
practice. Together, our trial provides important evidence 
for patients with acute coronary syndrome after 
successful PCI in whom early de­escalation is considered 
as an alternative strategy.
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Dual antiplatelet therapy guided by platelet function testing
Oral P2Y12 receptor inhibitors are key for secondary 
prevention of atherothrombotic events in patients 
with acute coronary syndromes, in particular those 
undergoing percutaneous coronary intervention (PCI)1. 
Prasugrel and ticagrelor are more potent than clopidogrel, 
which is characterised by increased rates of high on-
treatment platelet reactivity (HPR), a known marker for 
recurrent ischaemic events, including stent thrombosis.2 
This characteristic could explain the greater reduction 
in atherothrombotic events, albeit at the expense of 
more bleeding, associated with prasugrel and ticagrelor 
therapy among patients with acute coronary syndromes 
undergoing PCI.1 These observations have stimulated 
research aimed at understanding how to implement 
platelet function testing (PFT) to guide the selection of 
P2Y12 inhibiting therapies.3 However, previous randomised 
controlled trials (RCTs) using PFT have failed to show 
any effect on clinical outcomes and thus PFT is not 
recommended for routine use.4–7
In The Lancet, Dirk Sibbing and colleagues8 report the 
results of the TROPICAL-ACS trial, which investigated 
the safety and efficacy of early de-escalation of 
antiplatelet treatment from prasugrel to clopidogrel 
guided by PFT. 2610 patients with acute coronary 
syndrome undergoing PCI were randomly assigned 
to standard treatment with prasugrel for 12 months 
(control group; n=1306) or a de-escalation regimen 
(1 week prasugrel followed by 1 week of clopidogrel and 
PFT-guided maintenance therapy with clopidogrel or 
prasugrel from day 14 after hospital discharge; guided 
de-escalation group; n=1304). The primary endpoint (a 
composite of ischaemic and bleeding events at 1 year) 
was met (7·3% in the de-escalation group vs 9·0% in 
the control group; pnon-inferiority=0·0004; hazard ratio [HR] 
0·81 [95% CI 0·62–1·06], psuperiority=0·12), supporting the 
non-inferiority hypothesis of a guided de-escalation 
strategy compared with standard treatment with 
prasugrel (control). De-escalation did not result in an 
increase in ischaemic events (2·5% in the de-escalation 
group vs 3·2% in the control group; pnon-inferiority=0·0115), 
and there were no differences in the key secondary 
endpoint of Bleeding Academic Research Consortium 
criteria type 2 or higher bleeding (4·9% in the de-
escalation group vs 6·1% in the control group; HR 0·82 
[95% CI 0·59–1·13]; p=0·2257). The authors should be 
commended for this investigation, which is the first to 
my knowledge to test PFT-guided de-escalation therapy 
in patients with acute coronary syndrome undergoing 
PCI and meets its primary endpoint (appendix).4–8 
Indeed, differences in trial design, patient risk-profiles, 
and antiplatelet treatment regimens, among other 
variables, might explain the different outcomes across 
RCTs (appendix).4–8 Additionally, TROPICAL-ACS further 
expands on the topic of de-escalation, which has 
yielded conflicting findings in recently reported studies 
performed without PFT guidance.9,10
Based on the non-inferiority trial design, the 
take-home message of TROPICAL-ACS is that, in 
patients with acute coronary syndrome undergoing 
PCI, PFT-guided selection of P2Y12 inhibiting therapy 
could represent an alternative approach to a standard 
strategy of prasugrel use. Although it might be argued 
that the non-inferiority margin of 30% is broad, a 
post-hoc analysis showed that the non-inferiority was 
maintained by applying a margin of 10%. The absence 
of an increase in ischaemic events, but no reduction in 
bleeding complications, needs to be viewed in light of 
the trial strategy. In fact, while the PFT-guided strategy 
in TROPICAL-ACS helped to prevent ischaemic events by 
minimising the HPR status, this could have contributed 
to the absence of differences in bleeding between groups 
due to the fact that following de-escalation about 40% 
of patients had HPR and required escalation to prasugrel 
therapy, reducing the chances to observe a safety 
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benefit.8 From a practical perspective, a strategy of PFT-
guided de-escalation therapy might be useful in patients 
who might not be suitable for prolonged therapy with 
potent P2Y12 inhibitors, such as those at increased risk of 
bleeding or with limited access to extended treatment 
with the more costly prasugrel. Indeed, bleeding 
concerns and socioeconomic factors are key contributors 
to de-escalation therapy in real-world practice.11
There are some limitations of TROPICAL-ACS. First, 
although easy-to-use PFT is broadly available, there are 
a substantial number of HPR patients after de-escalation 
who then need to escalate therapy. This so-called back 
and forth management of antiplatelet therapy can be a 
source of confusion for some patients and might also be 
challenging to implement if patients cannot easily access 
centres that conduct PFT. Moreover, multiple factors 
can contribute to the variability in PFT results and thus 
defining the HPR status.3 Strategies that can overcome the 
above mentioned limitations are needed. To this extent, 
genetic testing might be of potential value and is currently 
under investigation.12 Although prasugrel and ticagrelor 
achieve similar levels of P2Y12 inhibition, it might be 
argued that the study findings cannot be extrapolated 
to ticagrelor because its off-target effects have been 
advocated to contribute to its overall benefits.1 Another 
consideration to be made is that the study findings 
cannot be applied to all patients with acute coronary 
syndromes because elderly individuals, patients with a 
previous cerebrovascular event, and those with medically 
managed acute coronary syndrome were excluded.
Despite the diagnostic value of PFT, over the past 
decade, RCTs have failed to show its role in guiding 
the choice of antiplatelet therapy. In turn, PFT has 
struggled to find a space in routine clinical practice. The 
experience from previous studies led to the design of the 
TROPICAL-ACS trial, the results of which now provide 
additional insights on how to use PFT to help select a 
P2Y12 inhibitor, thus suggesting a potential resurgence of 
a nearly abandoned instrument. Future research should 
build upon TROPICAL-ACS to help to define antiplatelet 
treatment approaches associated with optimal safety and 
efficacy performance profiles for the individual patient.
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